Artios Pharma to Attend Upcoming Conferences in February and March 2021

February 18, 2021
Press release

 

Cambridge, 16 February 2021: Artios Pharma (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announces it is scheduled to participate in the following upcoming virtual conferences:

LifeSci Partners Precision Oncology Day

17 February 2021

Niall Martin, Chief Executive Officer at Artios Pharma will present an overview of the company at 10.00am ET.

A replay of the presentation will be available to view after the conference on the Artios website.

10th Annual SVB Leerink Virtual Global Healthcare Conference

22 -26 February 2021

Niall Martin, Chief Executive Officer, Tania Dimitrova, Chief Business Officer, and Abid Ansari, Chief Financial Officer will participate in 1 x 1 meetings.

Barclays Healthcare Conference 2021

9 -11 March 2021

Tania Dimitrova, Chief Business Officer at Artios Pharma will present an overview of the company at 9.45am ET on Tuesday 9 March.

Niall Martin, Chief Executive Officer, Tania Dimitrova, Chief Business Officer, and Abid Ansari, Chief Financial Officer will participate in 1:1 meetings.

A replay of the presentation will be available to view after the conference on the Artios website.

END

For more information about Artios Pharma Ltd., please contact:

Investor Contact:

Abid Ansari, Chief Financial Officer

E: Abid.Ansari@artiospharma.com

 Media Contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Manel Mateus

E: artios@optimumcomms.com

Tel: +44 (0)20 3922 1906

 About Artios Pharma Limited

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer.  The Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib.  It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers, including Phase I/IIa clinical studies in 2021 for its ATR inhibitor ART0380 in treating DDR defective tumours, and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Merck KGaA, Darmstadt, Germany has the right to opt into exclusive development and commercialization of compounds on up to eight targets and Artios to receive up to US$860 million total milestones per target. It is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA. www.artiospharma.com

 

Contact us

Reach out to us.